

**HYOSCYAMINE ER- hyoscyamine sulfate tablet, extended release
Pharma Packaging Solutions, LLC dba Tjopack LLC**


Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

**Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg
Rx only
(Packaged by Pharma Packaging Solutions, LLC dba Tjoapack LLC)**

DESCRIPTION

Hyoscyamine sulfate extended-release tablets contain 0.375 mg of hyoscyamine sulfate in a formulation designed for oral b.i.d. dosage.

Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is $(C_{17}H_{23}NO_3)_2 \cdot H_2SO_4 \cdot 2H_2O$ and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, α -(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure:



Each tablet also contains as inactive ingredients: calcium phosphate dibasic, ethylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and stearic acid.

CLINICAL PHARMACOLOGY

Hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, the cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. At therapeutic doses, it is completely devoid of any action on autonomic ganglia. Hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Hyoscyamine

sulfate also controls excessive pharyngeal, tracheal, and bronchial secretions.

Hyoscyamine sulfate is absorbed totally and completely by oral administration. Once absorbed, hyoscyamine sulfate disappears rapidly from the blood and is distributed throughout the entire body: the half-life of hyoscyamine sulfate is 2 to 3½ hours.

Hyoscyamine sulfate is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Hyoscyamine sulfate passes the blood brain barrier and the placental barrier.

Hyoscyamine sulfate extended-release tablets releases 0.375 mg hyoscyamine sulfate at a controlled and predictable rate for 12 hours. The mean peak plasma concentration occurred at 4.20 hours. The mean (\pm SEM) apparent plasma elimination half-life is 7.47 hours (\pm 0.60). Tablets may not completely disintegrate and may be excreted by some patients.

INDICATIONS AND USAGE

Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon).

Hyoscyamine sulfate extended-release tablets are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a "drying agent" in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.

CONTRAINDICATIONS

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.

WARNINGS

In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or

other machinery or to perform hazardous work while taking this drug.

Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, euphoria, anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.

PRECAUTIONS

General

Use with caution in patients with: autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hypertension, and renal disease. Investigate any tachycardia before giving any anticholinergic drugs since they may increase the heart rate. Use with caution in patients with hiatal hernia associated with reflux esophagitis.

Information For Patients

Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.

Use of hyoscyamine sulfate may decrease sweating resulting in heat prostration, fever or heat stroke; febrile patients or those who may be exposed to elevated environmental temperatures should use caution. Tablets may not completely disintegrate and may be excreted by some patients.

Drug Interactions

Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.

Antacids may interfere with the absorption of hyoscyamine sulfate.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

No long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of hyoscyamine sulfate; however, 40 years of marketing experience with hyoscyamine sulfate shows no demonstrable evidence of a problem.

Pregnancy - Pregnancy Category C

Animal reproduction studies have not been conducted with hyoscyamine sulfate. It is also not known whether hyoscyamine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hyoscyamine sulfate should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Hyoscyamine sulfate is excreted in human milk. Caution should be exercised when hyoscyamine sulfate is administered to a nursing woman.

Geriatric Use

Reported clinical experience has not identified differences in safety between patients aged 65 and over and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

To report SUSPECTED ADVERSE REACTIONS, contact Wallace Pharmaceuticals at 1-800-619-6344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ADVERSE REACTIONS

All of the following adverse reactions have been reported with hyoscyamine sulfate. Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; constipation; bloated feeling; abdominal pain; diarrhea; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); short-term memory loss; hallucinations; and decreased sweating.

OVERDOSAGE

The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation.

Measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). Excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.

In rats, the LD₅₀ for hyoscyamine is 375 mg/kg. Hyoscyamine sulfate is dialyzable.

DOSAGE AND ADMINISTRATION

Dosage may be adjusted according to the conditions and severity of symptoms.

Adults And Pediatric Patients 12 Years Of Age And Older

1 to 2 tablets every 12 hours. Do not crush or chew tablets. Do not exceed 4 tablets in 24 hours.

HOW SUPPLIED

Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg are white, capsule-shaped tablets. They are coded "AP" on one side and "115" on the other.

Bottles of 100 tablets NDC 75929-057-10

Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Please refer to current USP.

Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.

KEEP OUT OF REACH OF CHILDREN

Also available as:

| | Dosage Strength | Package Size | NDC |
|--|------------------------|---------------------|--------------|
| Hyoscyamine Sulfate Tablets, USP | 0.125 mg | 100 | 75929-055-10 |
| Hyoscyamine Sulfate Sublingual Tablets | 0.125 mg | 100 | 75929-056-10 |

Distributed by:
Wallace Pharmaceuticals Inc.
Somerset, New Jersey 08873-4120
©2018 Mylan Pharmaceuticals Inc

WALLACE and  are trademarks of Wallace Pharmaceuticals Inc., a Mylan company

IN-1151-03 Rev. 3/2018

Printed in USA

70011278

PRINCIPAL DISPLAY PANEL - Hyoscyamine ER .375 mg

NDC 75929-057-10

100 tablets

**Hyoscyamine Sulfate
Extended-Release
Tablets**

0.375 mg

Rx only

Each tablet contains 0.375 mg hyoscyamine sulfate, USP.

USUAL DOSAGE: Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every 12 hours.

See package insert for full prescribing information.

Dispense in tight, light-resistant containers as defined in USP/NF with child-resistant closure.

KEEP OUT OF REACH OF CHILDREN.

Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Please refer to current USP.

Distributed by: Wallace Pharmaceuticals Inc.
Somerset, NJ 08873-4120, USA

For medical inquiries call 1-800-619-6344

©2018 Mylan Pharmaceuticals Inc.

LB-115103-03 REV 3/2018

NDC
100 tablets

**Hyoscyamine Sulfate
Extended-Release
Tablets**

0.375 mg

Rx only

WALLACE
PHARMACEUTICALS

Each tablet contains 0.375 mg hyoscyamine sulfate, USP.
USUAL DOSAGE: Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every 12 hours. See package insert for full prescribing information.
Dispense in tight, light-resistant containers as defined in USP/NF with child-resistant closure.
KEEP OUT OF REACH OF CHILDREN.
Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Please refer to current USP.
Distributed by: Wallace Pharmaceuticals Inc.
Somerset, NJ 08873-4120, USA
For medical inquiries call 1-800-619-6344
©2018 Mylan Pharmaceuticals Inc.
LB-115103-03 REV 3/2018

GTIN XXXXXXXXXXXXX
S/N XXXXXXXXXXXXX
EXP MM YYY
LOT XXXXXXXX

HYOSCYAMINE ER

hyoscyamine sulfate tablet, extended release

Product Information

| | | | |
|--------------------------------|-------------------------|---------------------------|---------------|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:75929-057 |
| Route of Administration | ORAL | | |

Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength |
|---|-------------------|----------|
| HYOSCYAMINE SULFATE (UNII: 528V92884) / HYOSCYAMINE | | |

| | | |
|---|---------------------|----------|
| HYOSCYAMINE SULFATE (UNII: FZR8V8ZB84) (HYOSCYAMINE - UNII:PX44XO846X) | HYOSCYAMINE SULFATE | 0.375 mg |
|---|---------------------|----------|

Product Characteristics

| | | | |
|-----------------|----------------------|---------------------|----------|
| Color | white | Score | no score |
| Shape | OVAL (capsule shape) | Size | 15mm |
| Flavor | | Imprint Code | AP;115 |
| Contains | | | |

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|--|----------------------|--------------------|
| 1 | NDC:75929-057-10 | 100 in 1 BOTTLE; Type 0: Not a Combination Product | 05/01/2016 | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|-----------------------|--|----------------------|--------------------|
| unapproved drug other | | 05/01/2016 | |

Labeler - Pharma Packaging Solutions, LLC dba Tjopack LLC (928861723)

Establishment

| Name | Address | ID/FEI | Business Operations |
|--------------------------------|---------|-----------|------------------------|
| Sovereign Pharmaceuticals, LLC | | 623168267 | manufacture(75929-057) |

Establishment

| Name | Address | ID/FEI | Business Operations |
|--|---------|-----------|---------------------|
| Pharma Packaging Solutions, LLC dba Tjoapack LLC | | 928861723 | pack(75929-057) |

Revised: 8/2023

Pharma Packaging Solutions, LLC dba Tjopack LLC